Innate Pharma Stock Debt To Equity
| IPH Stock | EUR 1.43 0.10 6.54% |
Innate Pharma fundamentals help investors to digest information that contributes to Innate Pharma's financial success or failures. It also enables traders to predict the movement of Innate Stock. The fundamental analysis module provides a way to measure Innate Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innate Pharma stock.
Innate |
Innate Pharma Company Debt To Equity Analysis
Innate Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Innate Pharma Debt To Equity | 2.70 % |
Most of Innate Pharma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Innate Pharma has a Debt To Equity of 2.7%. This is 94.96% lower than that of the Biotechnology sector and 86.05% lower than that of the Health Care industry. The debt to equity for all France stocks is 94.46% higher than that of the company.
Innate Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in debt to equity category among its peers.
Innate Fundamentals
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 86.87 M | |||
| Shares Outstanding | 80.2 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 125.20 X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 3.04 X | |||
| Revenue | 12.11 M | |||
| Gross Profit | (22.3 M) | |||
| EBITDA | (47.9 M) | |||
| Net Income | (52.81 M) | |||
| Cash And Equivalents | 103.76 M | |||
| Cash Per Share | 2.62 X | |||
| Total Debt | 46.5 M | |||
| Debt To Equity | 2.70 % | |||
| Current Ratio | 1.62 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (58.46 M) | |||
| Earnings Per Share | (0.27) X | |||
| Target Price | 6.7 | |||
| Number Of Employees | 213 | |||
| Beta | 0.33 | |||
| Market Capitalization | 224.71 M | |||
| Total Asset | 267.5 M | |||
| Retained Earnings | (7 M) | |||
| Working Capital | 192 M | |||
| Current Asset | 252 M | |||
| Current Liabilities | 60 M | |||
| Z Score | 2.4 | |||
| Net Asset | 267.5 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.